Cover Image

The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy

Lucrezia Piccioli, Michele Arcopinto, Andrea Salzano, Roberta D'Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, Alberto M. Marra
  • Lucrezia Piccioli
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Michele Arcopinto
    AORN “A. Cardarelli”, Emergency Department, Italy
  • Andrea Salzano http://orcid.org/0000-0003-2352-2103
    Federico II University of Naples, Department of Translational Medical Sciences University of Leicester, Glenfield Hospital, Italy
  • Roberta D'Assante
    IRCCS SDN Naples, Italy
  • Alessandra Schiavo
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Francesca M. Stagnaro
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Anna Lombardi
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Veronica Panicara
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Pietro Valente
    Federico II University of Naples, Department of Translational Medical Sciences, Italy
  • Giuseppe Vitale
    Buccheri La Ferla Fatebenefratelli Hospital, Cardiovascular Rehabilitation Unit, Italy
  • Filippo M. Sarullo
    Buccheri La Ferla Fatebenefratelli Hospital, Cardiovascular Rehabilitation Unit, Italy
  • Francesco Giallauria
    Federico II University of Naples, Department of Translational Medical Sciences, Italy

Abstract

Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values.  Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).

Keywords

Chronic heart failure; growth hormone; IGF-1; anabolic deficiency; biomarker; outcomes.

Full Text:

PDF
Submitted: 2018-06-19 22:13:18
Published: 2018-09-05 15:01:52
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
46

Views:
PDF
19

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Lucrezia Piccioli, Michele Arcopinto, Andrea Salzano, Roberta D'Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, Alberto M. Marra

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy